Side effects - Heart - Chronic Myeloid Leukemia - CML
VIDEOS
Summary of Cardiac Effects of NILOTINIB and IMATINIB in Patients Enrolled in ENESTND Trial
May 31, 2011, Oncology.TV
CLINICAL TRIALS
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
FORUMS
Afib or Retirement doesn't seem to be good for my health LLS
ARTICLES
1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML
April 9, 2018, Oncology Nurse Advisor
Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study
December 15, 2017, PublMed
Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
December 3, 2016, ASH 2016
BCR-ABL Tyrosine Kinase Inhibitors May Increase Cardiovascular Events in Chronic Myeloid Leukemia
February 16, 2016, Cancer Therapy Advisor
CML arterial adverse events rate dependent on TKI choice
October 22, 2015, News Medical
Life-saving cancer drug can also cause heart damage: Study
February 14, 2014, Ottawa Citizen
Ageing is a risk factor in imatinib mesylate cardiotoxicity
February 6, 2014, PublMed
Nilotinib-Associated Vascular Events.
May 23, 2012, PublMed
Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubLMed
FDA Drug Safety Communication: Sprycel (dasatinib) and risk of pulmonary arterial hypertension
November 10, 2011, U.S. Food and Drug Administration
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
August 2010, Leukemia Research
Reversible Cardiotoxicity with tyrosine kinase inhibitors
February 2010, Clinical advances In Hematology & Oncology
Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin
2009 ASCO annual meeting
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
July 2009, Journal Blood
Leukemia Drug May Improve Stroke Treatment
June 2008, WebMed
Gleevec – Same Drug, Twin Benefits?
June 2008, The Money Times
Leukemia pill may improve stroke treatment: study
June 2008, Canada.com
Cancer Drug Gleevec Could Fight Stroke
June 2008, HealthDay - eVitamine
Cardiotoxicity of imatinib is "a surprise"
July 2006, Heartwire
Summary of Cardiac Effects of NILOTINIB and IMATINIB in Patients Enrolled in ENESTND Trial
May 31, 2011, Oncology.TV
CLINICAL TRIALS
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
FORUMS
Afib or Retirement doesn't seem to be good for my health LLS
ARTICLES
1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML
April 9, 2018, Oncology Nurse Advisor
Peripheral Artery Occlusive Disease Among Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Case-Control Study
December 15, 2017, PublMed
Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
December 3, 2016, ASH 2016
BCR-ABL Tyrosine Kinase Inhibitors May Increase Cardiovascular Events in Chronic Myeloid Leukemia
February 16, 2016, Cancer Therapy Advisor
CML arterial adverse events rate dependent on TKI choice
October 22, 2015, News Medical
Life-saving cancer drug can also cause heart damage: Study
February 14, 2014, Ottawa Citizen
Ageing is a risk factor in imatinib mesylate cardiotoxicity
February 6, 2014, PublMed
Nilotinib-Associated Vascular Events.
May 23, 2012, PublMed
Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubLMed
FDA Drug Safety Communication: Sprycel (dasatinib) and risk of pulmonary arterial hypertension
November 10, 2011, U.S. Food and Drug Administration
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
August 2010, Leukemia Research
Reversible Cardiotoxicity with tyrosine kinase inhibitors
February 2010, Clinical advances In Hematology & Oncology
Effect of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin
2009 ASCO annual meeting
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
July 2009, Journal Blood
Leukemia Drug May Improve Stroke Treatment
June 2008, WebMed
Gleevec – Same Drug, Twin Benefits?
June 2008, The Money Times
Leukemia pill may improve stroke treatment: study
June 2008, Canada.com
Cancer Drug Gleevec Could Fight Stroke
June 2008, HealthDay - eVitamine
Cardiotoxicity of imatinib is "a surprise"
July 2006, Heartwire
